Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0240066 (iron deficiency)
 7,156 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The objective of this study was to investigate whether the measurement of serum soluble transferrin receptor could detect subclinical iron deficiency in adolescent girls, and to assess the possible specificity-compromising effects of growth, menarche, and intensive physical activity. The study population consisted of 191 physically active (control) girls aged 9-15 years. Dietary iron intake was estimated at baseline, and after 6 and 12 months. Iron status of the subjects was assessed by haematological laboratory tests at 6 and 12 months. A 3-month iron and multivitamin supplementation was started after the visit at 6 months. The supplementation consistently decreased soluble transferrin receptor concentrations in subjects with initial values greater than 2.4 mg/l, which was determined by regression analysis to be the cut-off value for iron-deficient erythropoiesis. The 95% reference interval in the iron-replete subjects (0.9-2.4 mg/l) was consistent with this finding. In our population, the incidence of subclinical iron deficiency was 10%. Growth or physical activity had no effect on the iron status. This study shows that, similarly to adults, soluble transferrin receptor measurement can be used to detect subclinical iron deficiency in adolescents (competitive athletes or normal controls). We suggest that soluble transferrin receptor concentrations above 2.4 mg/l indicate clinically relevant iron deficiency in adolescents.
 ...
PMID:Increased serum soluble transferrin receptor concentration detects subclinical iron deficiency in healthy adolescent girls. 1266 8

We report the case of a patient with a severe chronic radiation enteropathy. She had been dependent on red cell transfusions for many years. On admission, she displayed anemia (8.6 g/dL) resulting from both inadequate EPO production and a functional iron deficiency. A 3-wk IV iron sucrose treatment (200 mg once weekly) resulted in an increased reticulocyte count, but did not raise the hemoglobin (Hb) level. The adjunction of epoetin alpha (10,000 IU three times a week) made it possible to reach the normal range (12.9 g/dL) after a 17-wk treatment. As the anti-anemic treatment discontinued, the Hb level decreased to 11.1 g/dL within 2 wk. Giving EPO again (10,000 IU twice a week) failed to maintain the Hb level, which dropped under basal values (7.8 g/dL). In contrast, a second combination EPO/iron sucrose did restore a normal Hb level and maintained it. This case report supports the combination of EPO and IV iron supplementation in patients with anemia of chronic disease and either an impaired iron absorption or intolerance to oral iron.
 ...
PMID:Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy: a case report. 1451 81